Lapatinib-induced senescent-like phenotype in HER2-positive breast cancer cells.


583 Background: Resistance to HER2 targeted therapies is a significant clinical problem. To study acquired resistance to the dual EGFR/HER2 tyrosine kinase inhibitor lapatinib (L) in breast cancer, we conditioned HER2 positive breast cancer cell lines with L for 6 months. In HCC1419 cells, L conditioning caused growth arrest which was only reversed when L… (More)


Cite this paper

@article{McDermott2011LapatinibinducedSP, title={Lapatinib-induced senescent-like phenotype in HER2-positive breast cancer cells.}, author={Miranda McDermott and Brigid C. Browne and John P. A. Crown and Nora M O'brien and Dennis J. Slamon and N. O'Donovan}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2011}, volume={29 15_suppl}, pages={583} }